Use of Fluoxetine to Augment the Inter-Ictal Hypercapnic Ventilatory Response in Patients with Epilepsy: A Pilot Study.
Neurol India
; 70(5): 2125-2129, 2022.
Article
en En
| MEDLINE
| ID: mdl-36352620
ABSTRACT
Background:
Severe peri-ictal respiratory dysfunction is a potential biomarker for high SUDEP risk and correlates with an attenuated hypercapnic ventilatory response (HCVR). Prior studies suggest a potential role for selective serotonergic reuptake inhibitors in modifying the HCVR, but this approach has not been studied in the epilepsy population.Objectives:
To assess the feasibility of using fluoxetine to augment HCVR in epilepsy patients. Methods andMaterial:
An inter-ictal HCVR was measured using a CO2 rebreathing technique in patients with epilepsy aged 18-75 years. Eligible participants were randomized to fluoxetine or placebo, and the HCVR was repeated at the end of week 4. Primary outcomes were recruitment and retention rate.Results:
Of the 30 subjects enrolled, 22 were randomized (mean 3.8 subjects/3 months), with a retention rate of 100% in fluoxetine and 95% in placebo.Conclusions:
Our results demonstrate feasibility for a larger definitive future study to assess the efficacy of fluoxetine in augmenting HCVR.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fluoxetina
/
Epilepsia
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Neurol India
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos